Gutturbes

Gutturbes is a pharmaceutical product that contains the non‑steroidal anti‑inflammatory drug flurbiprofen as its active ingredient. The preparation is marketed in the European Union, with the specific strength and dosage form not disclosed in the available data. It is intended for oropharyngeal administration and is classified as an analgesic and anti‑inflammatory agent. Gutturbes belongs to the NSAID drug class and works by inhibiting cyclooxygenase enzymes.

Gutturbes is indicated for the symptomatic relief of discomfort in the mouth and throat. It is used when mild to moderate pain or inflammation affects the oropharyngeal region.

- Relief of sore throat associated with viral or bacterial infections. - Reduction of inflammation in the oropharyngeal mucosa. - Management of mild to moderate pain caused by oral lesions, such as aphthous ulcers. - Adjunctive treatment for postoperative discomfort after minor oral procedures. - Temporary alleviation of discomfort from dental irritation or gingivitis. - Supportive care for patients with throat irritation due to environmental irritants such as smoke or dry air.

The safety profile of Gutturbes reflects the typical effects observed with topical NSAID preparations used in the mouth and throat. Reported adverse events range from mild, transient sensations to rare but potentially serious reactions.

Common: - Temporary burning or stinging at the site of application. - Mild taste alteration or metallic sensation. - Slight dryness of the oral mucosa. - Minor nausea if the product is swallowed inadvertently. - Mild irritation or redness of the gingival tissue.

Serious: - Allergic reactions such as rash, itching, or swelling of the lips and tongue. - Signs of gastrointestinal bleeding, including black stools or vomiting blood. - Severe skin reactions like Stevens‑Johnson syndrome (very rare). - Rare occurrence of liver enzyme elevation requiring monitoring.

When considering Gutturbes, healthcare professionals should evaluate several precautionary factors to minimize risk and ensure appropriate use.

- Avoid use in patients with known hypersensitivity to flurbiprofen or other NSAIDs. - Use caution in individuals with a history of gastrointestinal ulceration or bleeding. - Assess renal function before prolonged use, especially in the elderly. - Do not apply to damaged oral mucosa or open wounds without medical advice. - Limit exposure in pregnant or breastfeeding women until safety is established. - Monitor for signs of systemic absorption if large amounts are used.

Gutturbes may interact with other medicines or substances that affect bleeding risk, renal function, or prostaglandin pathways. Identifying potential interactions helps to prevent adverse outcomes.

Avoid: - Concurrent use with systemic anticoagulants (e.g., warfarin) or antiplatelet agents, which may increase bleeding risk. - Combination with other NSAIDs or COX‑2 inhibitors, leading to additive gastrointestinal toxicity.

Use with caution: - Concomitant administration of diuretics or ACE inhibitors, which may affect renal clearance. - Use together with corticosteroids, as the combination can heighten ulcer risk. - Co‑administration with lithium, as NSAIDs can raise lithium serum levels. - If the patient is taking methotrexate, monitor for increased toxicity because NSAIDs can reduce renal elimination of methotrexate.